Parkinson’s disease (PD) is the second most common neurodegenerative disorder. Levodopa, introduced more than 40 years ago has since been the gold standard symptomatic treatment for PD. Compared with most other antiparkinsonian medications, levodopa has superior efficacy. However, it has long been known that after some years of treatment, most patients will develop complications, so called motor complications. Such motor complications arise as a consequence of poor pharmacokinetic and pharmacodynamic properties of levodopa. We are developing a series of compounds displaying full antiparkinsonian activity with long duration of action. Data show that such compounds can be administered orally and that they display full antiparkinsonian efficacy. Given the pharmacological profile these compounds are expected to display similar efficacy as levodopa but with considerable less propensity to induce long term motor complications.
Principle investigator: Per Svenningsson
Partner: TedroffCare AB (Joakim Tedroff)